First, I want to say god bless you for taking in a stray dog.
Second, below is the information I could find on the Prednisolone.
Immune-suppression with corticosteroids (such as prednisone) remains the center of therapy for Granulomatous Meningoencephalitis (GME). Once the disease is controlled, one may begin to gradually drop the steroid dose until the minimum dose required to control the disease is reached. This process can be expected to require 4 months or so. It is unusual for a patient to be able to fully discontinue medication but at least stronger immune-suppressive agents are rarely required.
A chemotherapy agent called procarbazine has been combined with prednisone to improve the legnth of GME remission. A study by Dr. Joan Coates et al. from the University of Missouri was published in the January/February issue of the Journal of the American College of Veterinary Internal Medicine. In this study, 21 dogs with GME were treated with both procarbazine and prednisone and outcomes compared to those of 11 dogs who were found to have GME on post-mortem and had received no treatment. Median survival time of the treated dogs was 14 months compared to less than one month for dogs receiving no treatment. Of the 21 dogs, 17 were able to reduce their steroid use or even discontinue it. Of the 21 dogs, 7 developed bone marrow suppression side effects and 3 dogs developed serious gastrointestinal side effects (hemorrhagic gastroenteritis). Although researchers concluded that procarbazine and prednisone was a more effective combination than prednisone alone, they did not actually include a group of dogs treated with prednisone alone in this study.
A new drug called leflunomide has been released to treat immune-mediated diseases of a type that includes GME. This is a relatively expensive treatment, which has limited use but it remains as a possible alternative to corticosteroid use for dogs that do not tolerate corticosteroid side effects.
Other drugs that show promise but have only been tested in a small number of patients include cyclosporine, an immunomodulator used to inhibit organ transplant rejection, and cytosine arabinoside, another chemotherapy agent that can be combined with prednisone.
If the GME is focal or localized, radiotherapy may be helpful. Radiation of the head or face can lead to infarction (abnormal clotting), which can in turn lead to seizures for periods as long as 5 to 6 months after therapy. Cataracts and dry eye are common results of radiotherapy should the eyes be included in the field of radiation. That said, many cases of focal GME have enjoyed complete resolution after radiation.
If seizures have been a manifestation of GME, either disseminated or focal, medication will be used to control the seizures. Anti-seizure medication is the same regardless of the cause of the seizures so something specific for GME seizures is not needed. For a review of anti-seizure medication see the section on seizure disorders.
Ophthalmic GME also uses oral corticosteroids for therapy but may also employ topical ones. If glaucoma results from GME then therapy for this is necessary. Again, therapy for this result of GME is addressed in a standard way; no specific GME glaucoma therapy is needed.
http://www.marvistavet.com/html/body_granulomatous_meningoencephali.html